📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 15:55
6 analysed today
FollowTelegram
6
Today
149,957
All-time analysed
42,989
Positive
6,669
Negative
91,589
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Titan Biotech Q1 FY27: Consolidated PAT Surges 58% YoY to ₹10.86 Cr
Titan Biotech reported a strong start to FY27 with consolidated revenue from operations reaching ₹59.17 Cr, a 27.2% increase over Q1 FY26. Net profit for the quarter surged 58.3% YoY to ₹10.86 Cr, significantly outperforming the ₹6.86 Cr reported in the same period last year. On a sequential basis, the performance was even stronger, with PAT growing 61.4% compared to Q4 FY26. The company's consolidated EPS improved to ₹2.63 from ₹1.83 YoY, reflecting robust operational efficiency.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a significant acceleration in both revenue and profit growth compared to the previous fiscal year's averages.
Why it mattersThe 58% jump in PAT suggests strong operating leverage and potentially improved product mix in the specialty chemicals segment, which is critical for a company currently trading at a high P/E of 55.0.
Consolidated Revenue (Q1): ₹59.17 CrConsolidated PAT (Q1): ₹10.86 CrYoY PAT Growth: 58.3%Q1 Revenue vs TTM Revenue: 28.7%Consolidated EPS: ₹2.63
📅 Short termThe stock is likely to react positively to the significant earnings beat and strong sequential growth in profitability.
📈 Long termIf the company maintains this quarterly run rate, it is on track to significantly exceed its FY26 annual PAT of ₹30 Cr, potentially justifying its premium valuation.
⚠ Risk flags
- Raw material cost volatility (consumed ₹29.93 Cr in Q1)
- High P/E valuation (55.0) increases sensitivity to any future earnings misses
Key Highlights
Consolidated Revenue from operations grew 27.2% YoY to ₹59.17 Cr
Consolidated Net Profit increased 58.3% YoY to ₹10.86 Cr from ₹6.86 Cr
Consolidated EPS rose to ₹2.63 for the quarter, up from ₹1.83 in Q1 FY26
Profit Before Tax (PBT) stood at ₹12.73 Cr, a 57% increase over the ₹8.11 Cr reported in Q1 FY26
Total Income for the quarter reached ₹60.98 Cr, representing 28.8% of the total FY26 annual income
👀 What to Watch
Monitor the sustainability of these margins in upcoming quarters and watch for any management commentary regarding raw material cost trends, which impacted expenses by ₹29.93 Cr this quarter.
Titan Biotech Q1 Results: Consolidated PAT Jumps 58% YoY to ₹10.86 Cr
Titan Biotech reported a strong start to FY27 with consolidated revenue growing 29.1% YoY to ₹60.98 Cr. Net profit for the quarter surged 58.3% YoY to ₹10.86 Cr, significantly outperforming the previous quarter's ₹6.73 Cr. Standalone operating margins showed notable improvement, reaching approximately 23.4% for the quarter compared to the TTM average of 18.7%. The company continues to operate with a very low debt-to-equity ratio of 0.03.
Confidence: HIGH
What changedTitan Biotech has reported a significant acceleration in both revenue and profit growth for Q1 FY27 compared to the flattish performance seen in the preceding quarter (March 2026).
Why it mattersThe sharp jump in profitability and margin expansion is critical for a company trading at a high P/E of 55.0, as it provides fundamental support for its valuation and high ROCE of 23%.
Consolidated Revenue (Q1 FY27): ₹60.98 CrConsolidated PAT (Q1 FY27): ₹10.86 CrYoY PAT Growth: 58.3%QoQ Revenue Growth: 21.2%Consolidated EPS: ₹2.63Revenue vs TTM Revenue: 29.6%
📅 Short termThe stock is likely to react positively in the short term as the earnings growth (58% PAT jump) significantly exceeds the recent quarterly run rate.
📈 Long termStructural growth in specialty chemicals and the company's ability to maintain high margins while remaining debt-free are positive long-term indicators, though the high P/E leaves little room for execution errors.
⚠ Risk flags
- High valuation (P/E 55.0)
- Potential volatility in raw material costs
- Concentration in specialty chemicals segment
Key Highlights
Consolidated Net Profit increased 58.3% YoY to ₹10.86 Cr from ₹6.86 Cr in June 2025
Total Income from operations grew 29.1% YoY to ₹60.98 Cr
Consolidated Basic EPS rose to ₹2.63 from ₹1.66 in the year-ago period
Standalone Profit Before Tax (PBT) stood at ₹12.73 Cr, a 57% increase over June 2025
Quarterly revenue of ₹60.98 Cr represents approximately 30% of the total TTM revenue of ₹206 Cr
👀 What to Watch
Investors should monitor the sustainability of the current 23%+ operating margins in upcoming quarters. Key focus should remain on whether this growth is driven by volume expansion or favorable raw material pricing in the specialty chemicals segment.
